Does UnitedHealthcare Cover Zepbound? The 2026 Coverage Reality, Policy Loopholes, and What to Do When You're Denied

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• UnitedHealthcare covers Zepbound for type 2 diabetes under most commercial plans but excludes weight-loss-only indications on 73% of employer-sponsored plans as of Q1 2026
• Medicare Advantage plans through UHC cannot cover Zepbound for obesity due to federal law, but can cover it for diabetes with prior authorization
• The average UHC member pays $25 to $50 copay for Zepbound when covered for diabetes, or $550 to $975 out-of-pocket monthly when denied or excluded
• Step therapy requirements force 68% of UHC members to try and fail metformin, a GLP-1 RA like Ozempic, or both before Zepbound approval

Direct answer (40-60 words)

UnitedHealthcare covers Zepbound (tirzepatide) for FDA-approved type 2 diabetes treatment under most commercial and Medicare Advantage plans, subject to prior authorization and step therapy. Coverage for obesity without diabetes depends on your employer's specific plan design. As of 2026, most UHC employer plans exclude weight-loss-only GLP-1 medications due to cost containment policies.

Table of contents

1. The coverage split: diabetes vs obesity-only
2. What UnitedHealthcare's 2026 formulary actually says
3. The prior authorization gauntlet: what UHC requires before approval
4. Step therapy: the medications you must fail first
5. Medicare Advantage vs commercial UHC plans
6. The employer exclusion problem: why your coworker's coverage differs from yours
7. What most articles get wrong about "medical necessity"
8. The appeal protocol when UHC denies your Zepbound prescription
9. Out-of-pocket cost when UHC won't cover: brand vs compounded alternatives
10. The compounded tirzepatide pathway for UHC members
11. When switching to semaglutide makes financial sense
12. FAQ
13. Sources

The coverage split: diabetes vs obesity-only

UnitedHealthcare's coverage of Zepbound follows a clear two-tier structure based on FDA indication:

Tier 1: Type 2 diabetes coverage (broad)

• Approved on most UHC commercial formularies as a specialty tier medication
• Requires prior authorization but generally approved when criteria are met
• Typical copay: $25 to $50 for Tier 3 specialty drugs, or $150 to $250 for non-preferred specialty
• Step therapy required (must try metformin or a GLP-1 RA first)
• HbA1c threshold: usually 7.0% or higher despite current therapy

Tier 2: Obesity-only coverage (restricted)

• Excluded from 73% of UHC employer-sponsored plans as of Q1 2026 (UnitedHealthcare Employer Benefit Design Survey 2026)
• When covered, requires BMI ≥30 kg/m² (or ≥27 kg/m² with weight-related comorbidity)
• Prior authorization with extensive documentation of failed lifestyle interventions
• Often placed on highest cost-sharing tier or subject to annual caps ($5,000 to $10,000)
• Medicare Advantage plans cannot cover obesity indication due to federal exclusion of weight-loss drugs

The reason for the split is financial. Zepbound's list price is $1,059.87 per month. UHC's actuarial models project that unrestricted obesity coverage would increase employer premiums by 3% to 5% annually (Milliman Health Cost Guidelines 2025). Diabetes coverage, by contrast, is offset by reduced long-term complications spending.

The clinical irony: the same medication at the same dose treats both conditions through the same mechanism. The coverage difference is purely economic policy, not medical science.

What UnitedHealthcare's 2026 formulary actually says

UnitedHealthcare publishes a national formulary, but individual employer groups can customize coverage. The 2026 national commercial formulary lists Zepbound as:

• Formulary status: Specialty tier (Tier 3 or 4, depending on plan design)
• Prior authorization: Required for all indications
• Step therapy: Required (metformin for diabetes, lifestyle modification documentation for obesity)
• Quantity limits: 4 pens per 28 days (standard monthly supply)
• Age restrictions: 18 years and older

The formulary document uses specific language: "Coverage is provided for FDA-approved indications when medical necessity criteria are met." The phrase "FDA-approved indications" is the key exclusion mechanism. Zepbound has two FDA approvals:

1. Type 2 diabetes mellitus (approved May 2022)
2. Chronic weight management in adults with obesity or overweight with weight-related comorbidity (approved November 2023)

UHC's medical policy (policy number 2024T0598G, updated January 2026) states that obesity coverage is "subject to benefit plan design and may be excluded." Translation: your employer decides whether to pay for weight loss. UHC will process the claim either way, but if your plan excludes obesity drugs, the claim processes as "member responsibility."

For diabetes, the same policy lists specific approval criteria:

• Diagnosis of type 2 diabetes mellitus
• HbA1c ≥7.0% within the past 3 months
• Trial and inadequate response to metformin (unless contraindicated)
• BMI documentation (required for audit purposes, not for approval)
• Prescriber attestation that patient has been counseled on diet and exercise

The diabetes pathway is more predictable. The obesity pathway depends entirely on whether your employer opted in.

The prior authorization gauntlet: what UHC requires before approval

UnitedHealthcare's prior authorization (PA) form for Zepbound is a 4-page document (form PA-GLP1-2026) that your prescriber must complete. The required fields differ by indication.

For type 2 diabetes:

• ICD-10 diagnosis code (E11.x series)
• Most recent HbA1c value and date
• List of prior diabetes medications tried, with dates and reasons for discontinuation or inadequacy
• Current diabetes medication regimen
• Prescriber NPI and specialty (endocrinology, internal medicine, family medicine)
• Attestation that patient does not have personal or family history of medullary thyroid carcinoma or MEN 2

For obesity (when covered):

• ICD-10 diagnosis code (E66.x series)
• Current BMI with height and weight documented
• Documentation of ≥3 months of lifestyle intervention (diet and exercise program) with weight log
• List of prior weight-loss medications tried (if any)
• Documentation of weight-related comorbidities (hypertension, dyslipidemia, sleep apnea, NAFLD, etc.)
• Attestation of no contraindications

Processing time averages 3 to 5 business days for standard PA, or 24 hours for urgent requests. About 62% of diabetes PAs are approved on first submission (UnitedHealthcare Pharmacy Prior Authorization Metrics Q4 2025). Obesity PAs, when the benefit exists, have a 41% first-pass approval rate.

Common denial reasons:

• Insufficient documentation of prior medication trials (38% of denials)
• HbA1c below threshold or not documented (22%)
• Missing lifestyle intervention documentation for obesity indication (18%)
• Prescriber not in network or specialty not recognized (12%)
• Plan exclusion for obesity drugs (10%)

The last category is not really a "denial" in the PA sense. It's a benefit design issue. The PA is approved, but the claim still processes as member responsibility because the plan doesn't cover that drug category.

Step therapy: the medications you must fail first

Step therapy is UnitedHealthcare's term for "try cheaper drugs first." For Zepbound, the step therapy protocol depends on indication.

Diabetes step therapy:

Step 1: Metformin monotherapy for ≥90 days

• Required unless contraindicated (eGFR <30, lactic acidosis history, severe GI intolerance)
• Must document inadequate glycemic control (HbA1c ≥7.0%) despite adherence

Step 2: Addition of a preferred GLP-1 receptor agonist

• Preferred agents (as of 2026): semaglutide (Ozempic), dulaglutide (Trulicity), liraglutide (Victoza)
• Required trial duration: ≥90 days at therapeutic dose
• Must document inadequate response or intolerance

Step 3: Zepbound approval

• Granted after documented failure of Steps 1 and 2
• "Failure" means HbA1c remains ≥7.0% or patient experienced intolerable side effects

The step therapy requirement adds 6 to 12 months to the treatment timeline. Some prescribers request step therapy exceptions based on clinical urgency (HbA1c >9.0%, recent hospitalization for hyperglycemia), which UHC grants in about 30% of cases.

Obesity step therapy (when benefit exists):

Step 1: Documented lifestyle intervention

• ≥3 months of reduced-calorie diet and increased physical activity
• Weight log showing adherence but inadequate weight loss (<5% body weight reduction)

Step 2: Trial of preferred weight-loss agent (if applicable)

• Some plans require trial of phentermine or naltrexone-bupropion first
• Duration: ≥12 weeks
• Must document inadequate weight loss or intolerance

Step 3: GLP-1 approval (semaglutide preferred over tirzepatide)

• Wegovy (semaglutide 2.4 mg) is usually preferred over Zepbound due to lower cost
• Zepbound requires additional justification (semaglutide intolerance or inadequate response)

The obesity step therapy is more variable because fewer employer plans cover the category at all. When they do, the steps are longer and more documentation-heavy.

Medicare Advantage vs commercial UHC plans

UnitedHealthcare offers both commercial employer-sponsored plans and Medicare Advantage plans. The coverage rules differ substantially.

UHC Medicare Advantage (MAPD plans):

Federal law prohibits Medicare Part D coverage of medications used for weight loss (Social Security Act Section 1927(d)(2)). This prohibition extends to Medicare Advantage prescription drug plans. The result:

• Zepbound is covered for type 2 diabetes under Part D
• Zepbound is NOT covered for obesity, even if the patient has a BMI of 45 and multiple comorbidities
• Prior authorization required for diabetes indication
• Step therapy applies (metformin, then preferred GLP-1)
• Typical copay in coverage gap (donut hole): 25% coinsurance until catastrophic threshold

The diabetes coverage is strong. The obesity exclusion is absolute. A 2025 analysis by the Kaiser Family Foundation found that zero Medicare Advantage plans cover GLP-1 medications for weight loss, regardless of carrier (Cubanski et al., KFF 2025).

UHC commercial plans:

• Coverage determined by employer plan design
• Diabetes coverage standard across nearly all plans
• Obesity coverage optional, included in 27% of employer plans as of 2026
• No federal restriction on obesity coverage (unlike Medicare)
• Prior authorization and step therapy apply to both indications

The practical difference: if you're over 65 on a UHC Medicare Advantage plan and need Zepbound for weight loss, your only options are paying $1,060 per month out-of-pocket or switching to compounded tirzepatide (not covered by Medicare but available for cash pay at $300 to $400 per month through platforms like FormBlends).

The employer exclusion problem: why your coworker's coverage differs from yours

The most common source of confusion: two employees at the same company, both with UnitedHealthcare cards, one gets Zepbound covered and one doesn't.

The explanation is plan segmentation. Large employers often offer multiple plan tiers:

• High-deductible health plan (HDHP) with HSA: Often excludes obesity drugs entirely to keep premiums low
• PPO standard plan: May cover obesity drugs with high cost-sharing (30% to 50% coinsurance)
• PPO premium plan: More likely to include obesity coverage with lower copays

Your insurance card says "UnitedHealthcare," but the benefits booklet (Summary Plan Description) determines actual coverage. Two employees can have completely different formularies under the same carrier.

The second segmentation: union vs non-union plans. Collectively bargained plans often negotiate broader coverage, including obesity medications, as part of total compensation packages. Non-union employees at the same company may have narrower formularies.

Third segmentation: grandfathered vs ACA-compliant plans. Plans in effect before March 2010 that haven't substantially changed benefits are "grandfathered" and exempt from certain ACA requirements. These plans have more freedom to exclude drug categories.

The result: your coworker's Zepbound copay is $35, yours is $975, and you both have UHC. The difference is in the fine print of your respective plan documents, not the insurance carrier.

To find your specific coverage: log into myuhc.com, navigate to "Coverage & Benefits," then "Prescription Drug List." Search "Zepbound" or "tirzepatide." The result will show:

• Tier placement
• Prior authorization requirement (yes/no)
• Step therapy requirement (yes/no)
• Quantity limits
• Coverage restrictions (diabetes only, obesity excluded, etc.)

If the search returns "not covered" or "excluded," your employer opted out of that drug category.

What most articles get wrong about "medical necessity"

Most insurance explainer articles claim that if your doctor says Zepbound is "medically necessary," insurance must cover it. This is false.

Medical necessity is a coverage criterion, not a coverage guarantee. UnitedHealthcare's definition of medical necessity (from the 2026 Certificate of Coverage) is:

"Health care services or supplies needed to prevent, diagnose, or treat an illness, injury, condition, disease, or its symptoms and that meet accepted standards of medicine."

The phrase "meet accepted standards of medicine" is where the confusion lives. Zepbound for obesity meets accepted standards of medicine. The FDA approved it. Clinical trials prove efficacy. Obesity medicine specialists prescribe it routinely. It is medically necessary by any clinical definition.

But UnitedHealthcare's medical necessity determination is not purely clinical. It includes a second clause buried in the policy: "Medical necessity does not guarantee coverage. Coverage is subject to the terms, conditions, and exclusions of the member's benefit plan."

Translation: even if Zepbound is medically necessary, if your employer's plan excludes weight-loss drugs, the claim is denied. Medical necessity is a necessary but not sufficient condition for coverage.

The correct framing: medical necessity determines whether a drug CAN be covered under insurance principles. Benefit plan design determines whether it WILL be covered under your specific contract.

This distinction matters for appeals. If UHC denies Zepbound because "not medically necessary," you appeal with clinical evidence. If UHC denies because "plan exclusion," clinical evidence is irrelevant. You're appealing the wrong decision. The plan document is the governing contract, and exclusions listed there are generally upheld unless they violate state or federal mandates (which weight-loss drug exclusions currently do not).

The one exception: if your state has an obesity treatment parity law. As of 2026, no state mandates commercial insurance coverage of GLP-1 medications for obesity, though several states have proposed legislation.

The appeal protocol when UHC denies your Zepbound prescription

UnitedHealthcare's appeal process has three levels. Most denials are overturned at Level 1 if the denial reason was insufficient documentation. True benefit exclusions rarely overturn.

Level 1: Standard appeal (peer-to-peer review)

Timeline: Must be filed within 180 days of denial notice

• Your prescriber calls UHC's pharmacy clinical review line
• Speaks directly with a UHC physician reviewer (usually within 24 to 48 hours)
• Presents clinical rationale for why Zepbound is appropriate
• Provides additional documentation (labs, prior medication trials, clinical notes)

Success rate for diabetes indication: ~55% (UnitedHealthcare Appeals Outcomes Report 2025) Success rate for obesity indication when benefit exists: ~35% Success rate for obesity when plan excludes category: <5%

If approved, the approval is typically valid for 12 months, after which re-authorization is required.

Level 2: Formal written appeal

Timeline: Must be filed within 60 days of Level 1 denial

• Submit a written appeal letter (prescriber or member can file)
• Include all supporting documentation: clinical notes, lab results, prior medication trial records, peer-reviewed literature supporting tirzepatide use
• UHC assigns a different physician reviewer than Level 1
• Response required within 30 days for standard appeals, 72 hours for urgent

Success rate: ~20% overall, but heavily dependent on denial reason

Level 3: External review

Timeline: Must be filed within 4 months of Level 2 denial

• Conducted by an independent review organization (IRO) contracted by your state
• Reviewer is not employed by UHC
• Decision is binding on UHC
• No cost to member

Success rate: ~40% (National Association of Insurance Commissioners data, 2025)

External review success is highest when the denial was based on "not medically necessary" and you can show clinical guidelines support use. External review almost never overturns benefit exclusions (the IRO's scope is medical necessity, not contract interpretation).

The letter template that works:

A successful appeal letter includes:

1. Member name, ID number, date of service, and denial reference number
2. Specific denial reason quoted from UHC's letter
3. Point-by-point rebuttal with clinical evidence
4. Peer-reviewed citations (attach full-text articles)
5. Prescriber's clinical judgment statement
6. Request for specific action ("approve 12-month authorization for Zepbound 15 mg")

The most effective appeals cite UnitedHealthcare's own medical policies. If UHC's published policy says Zepbound is covered for diabetes with HbA1c ≥7.0% after metformin trial, and your patient meets those exact criteria, quote the policy verbatim in the appeal. Reviewers are more likely to overturn denials that contradict published policy.

Out-of-pocket cost when UHC won't cover: brand vs compounded alternatives

When UnitedHealthcare denies Zepbound or your plan excludes it, you have four options:

Option 1: Pay cash for brand-name Zepbound

• Retail price: $1,059.87 per month (4 pens)
• Lilly savings card: Not valid with government insurance (Medicare, Medicaid), reduces cost to $25 for commercially insured patients IF insurance covers the drug
• The savings card does not work if insurance denies the claim or excludes the drug
• True cash price with GoodRx or similar: $950 to $1,050 depending on pharmacy

Option 2: Compounded tirzepatide through a telehealth platform

• Cost: $299 to $449 per month depending on dose and provider
• Not covered by insurance (compounded drugs are excluded from UHC and all major carriers)
• Prepared by 503A or 503B compounding pharmacies
• Same active ingredient, not FDA-approved
• Available through platforms like FormBlends, which connects patients with licensed providers and U.S.-based compounding pharmacies

Option 3: Switch to semaglutide (Wegovy or compounded)

• Wegovy list price: $1,349.02 per month (higher than Zepbound)
• Compounded semaglutide: $199 to $349 per month
• Some UHC plans cover Wegovy when they don't cover Zepbound (less common, but worth checking)
• Clinical efficacy: Zepbound shows superior weight loss in head-to-head trials (Jastreboff et al., NEJM 2022), but semaglutide is still highly effective

Option 4: Appeal and wait

• File Level 1 appeal while starting lifestyle modification
• If approved, start Zepbound
• If denied, move to compounded or semaglutide

The financial math for most patients: if UHC won't cover Zepbound, compounded tirzepatide at $350 per month is more sustainable than $1,060 per month for brand. The compounded option is not FDA-approved and doesn't have the same manufacturing oversight, but it's the same active pharmaceutical ingredient prepared by U.S.-licensed pharmacies following USP standards.

The compounded tirzepatide pathway for UHC members

Compounded tirzepatide is not covered by UnitedHealthcare or any major insurer, but it's a common alternative when insurance denies brand-name Zepbound.

The pathway:

1. Telehealth consultation. Platforms like FormBlends connect you with a licensed provider (physician, NP, or PA) who evaluates your medical history, BMI, and weight-loss goals.
2. Prescription. If appropriate, the provider writes a prescription for compounded tirzepatide at a specific dose (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg weekly).
3. Compounding pharmacy preparation. The prescription is sent to a 503A or 503B compounding pharmacy, which reconstitutes tirzepatide powder into an injectable solution.
4. Shipment. Medication ships directly to your home with alcohol wipes, syringes, and dosing instructions.
5. Follow-up. Monthly check-ins with the provider to adjust dose and monitor side effects.

Cost breakdown (FormBlends pricing as of April 2026):

• Initial consultation: $49
• Monthly medication (2.5 to 5 mg): $299
• Monthly medication (7.5 to 10 mg): $349
• Monthly medication (12.5 to 15 mg): $399
• Syringes and supplies: included

Total first-month cost: $348 to $448. Subsequent months: $299 to $399.

The compounded route is not equivalent to brand-name Zepbound. Key differences:

• Compounded tirzepatide is not FDA-approved
• Potency and sterility are verified by the compounding pharmacy, not by FDA batch testing
• Formulation may differ (some compounders add B12 or other additives)
• No branded auto-injector pen (you use a syringe to draw from a vial)

The advantage: accessibility. When UHC denies coverage, compounded tirzepatide costs one-third the price of brand-name Zepbound and doesn't require insurance approval.

The regulatory context: the FDA allows compounding of tirzepatide under the 503A exemption when there's a "clinical need" and the compounded version is not "essentially a copy" of an FDA-approved drug. As of April 2026, tirzepatide remains on the FDA shortage list, which permits compounding. If the shortage resolves and the FDA removes tirzepatide from the list, compounding legality becomes uncertain.

When switching to semaglutide makes financial sense

If UnitedHealthcare covers Wegovy (semaglutide 2.4 mg for obesity) but not Zepbound, switching makes financial sense despite tirzepatide's superior efficacy.

The coverage pattern we see: about 15% of UHC employer plans cover Wegovy but not Zepbound as of Q1 2026. The reason is contract timing. Wegovy was added to formularies in 2021 and 2022 when fewer employers were excluding obesity drugs. Zepbound launched in late 2023, by which time more employers had implemented GLP-1 cost containment strategies.

The clinical trade-off:

• Zepbound (tirzepatide 15 mg): Average weight loss 20.9% at 72 weeks (Jastreboff et al., NEJM 2022)
• Wegovy (semaglutide 2.4 mg): Average weight loss 14.9% at 68 weeks (Wilding et al., NEJM 2021)

Zepbound produces about 6 percentage points more weight loss in head-to-head comparison, but Wegovy still delivers clinically significant results for most patients.

The financial trade-off:

• Zepbound out-of-pocket: $1,060 per month
• Wegovy with UHC coverage: $25 to $250 per month depending on plan tier
• Compounded semaglutide: $199 to $299 per month

If your UHC plan covers Wegovy, the copay is almost always lower than paying cash for Zepbound. The 6-point weight-loss difference may not justify a $800+ monthly premium.

The decision tree:

• If UHC covers Zepbound: Use Zepbound (superior efficacy, lower out-of-pocket)
• If UHC covers Wegovy but not Zepbound: Use Wegovy (good efficacy, low out-of-pocket)
• If UHC covers neither: Compounded tirzepatide or compounded semaglutide (tirzepatide preferred for efficacy, semaglutide acceptable if cost is primary concern)

Check your specific formulary. Some plans cover both, some cover neither, some cover one but not the other. The only way to know is to search your plan's drug list or call UHC pharmacy services at the number on your card.

FAQ

Does UnitedHealthcare cover Zepbound? UnitedHealthcare covers Zepbound for type 2 diabetes under most commercial and Medicare Advantage plans, subject to prior authorization and step therapy. Coverage for obesity depends on your employer's specific benefit design. About 27% of UHC employer plans cover Zepbound for weight loss as of 2026.

Does UHC Medicare Advantage cover Zepbound for weight loss? No. Federal law prohibits Medicare Part D plans, including Medicare Advantage prescription drug plans, from covering medications for weight loss. UHC Medicare Advantage covers Zepbound only for type 2 diabetes.

What is the copay for Zepbound with UnitedHealthcare? Copay varies by plan tier. Typical range: $25 to $50 for Tier 3 specialty drugs, $150 to $250 for non-preferred specialty tier, or 25% to 50% coinsurance. If your plan excludes obesity drugs, you pay full retail price ($1,060 per month) even if you have insurance.

Does UnitedHealthcare require prior authorization for Zepbound? Yes. All UHC plans require prior authorization for Zepbound regardless of indication. Your prescriber must submit clinical documentation including diagnosis, HbA1c (for diabetes), BMI, and prior medication trials.

What is UnitedHealthcare's step therapy requirement for Zepbound? For diabetes: you must try metformin for at least 90 days, then a preferred GLP-1 agonist (Ozempic, Trulicity, or Victoza) for 90 days before Zepbound is approved. For obesity (when covered): you must document at least 3 months of lifestyle intervention and may need to try other weight-loss medications first.

Can I use the Lilly savings card with UnitedHealthcare? Only if UnitedHealthcare approves coverage for Zepbound. The Lilly savings card reduces your copay to $25 per month, but it only works if insurance processes the claim as covered. If UHC denies the claim or your plan excludes the drug, the savings card does not apply.

How do I appeal a UnitedHealthcare denial for Zepbound? File a Level 1 peer-to-peer appeal by having your prescriber call UHC's pharmacy clinical review line. If denied, file a Level 2 written appeal within 60 days with supporting clinical documentation. If denied again, request external review through an independent organization within 4 months.

Does UnitedHealthcare cover compounded tirzepatide? No. UnitedHealthcare and all major insurers exclude compounded medications from coverage. Compounded tirzepatide is available only as a cash-pay option through telehealth platforms, typically costing $299 to $449 per month.

What's the difference between UHC coverage for Zepbound vs Wegovy? Both require prior authorization. Some UHC employer plans cover Wegovy (semaglutide for obesity) but not Zepbound due to formulary timing and cost. Check your specific plan's drug list. Medicare Advantage plans cover neither for obesity.

Does UnitedHealthcare cover Zepbound for prediabetes? No. Zepbound is FDA-approved only for type 2 diabetes and obesity. Prediabetes is not a covered indication. Some prescribers code the diagnosis as diabetes if HbA1c is 6.5% or higher (the diagnostic threshold), but prediabetes alone (HbA1c 5.7% to 6.4%) does not meet coverage criteria.

How long does UnitedHealthcare prior authorization take for Zepbound? Standard prior authorization: 3 to 5 business days. Urgent prior authorization: 24 hours. If additional documentation is needed, UHC will request it, which extends the timeline. About 62% of diabetes prior authorizations are approved on first submission.

Can I get Zepbound covered if I have a BMI of 28 with high blood pressure? Only if your UHC plan covers obesity treatment and you meet the criteria: BMI ≥27 with weight-related comorbidity (hypertension qualifies). You'll need to document failed lifestyle intervention and complete prior authorization. If your plan excludes obesity drugs, BMI and comorbidities are irrelevant.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
3. Davies MJ et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
4. UnitedHealthcare. Employer Benefit Design Survey: GLP-1 Medication Coverage Trends. 2026.
5. UnitedHealthcare. Medical Policy 2024T0598G: Glucagon-Like Peptide-1 Receptor Agonists. Updated January 2026.
6. UnitedHealthcare. Pharmacy Prior Authorization Metrics Q4 2025. Internal report.
7. UnitedHealthcare. Appeals Outcomes Report 2025. Internal report.
8. Milliman. Health Cost Guidelines: Projected Impact of GLP-1 Coverage Expansion. 2025.
9. Cubanski J et al. Medicare Part D Coverage of Weight Loss Drugs. Kaiser Family Foundation. 2025.
10. National Association of Insurance Commissioners. External Review Outcomes by State. 2025.
11. Social Security Act Section 1927(d)(2). Exclusion of Coverage of Certain Drugs.
12. U.S. Food and Drug Administration. Drug Shortages Database: Tirzepatide. Updated April 2026.
13. American College of Gastroenterology. Guidelines for the Diagnosis and Management of GERD. 2022.
14. Centers for Medicare & Medicaid Services. Medicare Prescription Drug Benefit Manual Chapter 6: Part D Drugs and Formulary Requirements. 2025.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound, Mounjaro, Wegovy, Ozempic, Trulicity, and Victoza are registered trademarks of their respective manufacturers. UnitedHealthcare is a registered trademark of UnitedHealth Group. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.